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Introduction
Method
Results
Discussion
• Individuals with psychiatric conditions, such as schizophrenia (SZ) and
bipolar disorders (BD), have a higher rate of smoking and have lower quit
rates compared to the general population.
• As a dopamine agonist, nicotine may help alleviate negative symptoms by
increasing abnormally low levels of dopamine in the prefrontal cortex and
mesolimbic system consistent with the dopamine deficit hypothesis
• The purpose of the study is to further explore the interactions of nicotine
and negative symptoms in a diverse population of individuals with serious
mental illness.
• Furthermore, research examining interactions of nicotine and negative
symptoms for individuals with schizophrenia compared to individuals with
bipolar disorder who experience psychotic symptoms has not been
conducted to our knowledge
• Consistent with the continuum of psychosis conceptualizations, the current 
study will examine rates of smoking in SZ and BP with psychotic features 
in order to provide additional information about shared symptoms and 
liabilities that may link schizophrenia and bipolar disorders. 
Hypothesis
• Based on the mechanism of nicotine, the current study expected higher 
rates of nicotine usage in groups experiencing negative symptoms as 
measured by the the Scale for the Negative Symptoms (SANS). 
• Specifically, we expect SZ and BDP to have similar behavioral patterns on 
our assessments and nicotine usage due to the similarity of their 
symptomatic features. In contrast, we expect BDN to have a lower rate of 
nicotine usage due to its lower level of negative symptoms compared to SZ 
and BDP.
Participants:
• 48 individuals diagnosed with BDN, 47 individuals diagnosed with BDP, 
and 50 individuals diagnosed with SZ. 
• Demographic information for each group can be found in Table 1. 
• There were no significant differences between groups on age, gender, or 
ethnicity.
• Based on the criteria of Kaiser-Guttman, PCA indicated that the SANS 
subscales is composed of six factors:
• Factor 1 measures Affective Flattening
• Factor 2 measures Anhedonia-Asociality
• Factor 3 measures Alogia
• Factor 4 measures Avolition-Apathy
• Factor 5 measures Affective Flattening, Alogia, and Avolition-Apathy
• Factor 6 measures Attention
• Factor scores measuring affective flattening, alogia, and attention were 
significantly different between groups (see Table 2).
• Attention was significantly different between nicotine and non-nicotine 
group (see Table 3). 
• There were no significant differences between nicotine and non-nicotine 
group on HDRS total scores.
• SANS Factor Scores measuring anhedonia and avolition significantly 
correlated with HDRS total scores (see Table 4). 
• Results suggested that the only difference in negative symptoms among 
the groups was for attention
• When the sample is divided into more homogenous subsets based on 
diagnostic category and nicotine usage, differential patterns of 
relationships of nicotine on attention were found. Specifically: 
• In schizophrenia, non-smoking and smoking were associated 
with attention.
• In bipolar disorder, non-smoking and smoking were not 
associated with attention. 
• Findings also indicate supporting evidence for the continuum 
conceptualization of psychosis. 
• Similar to schizophrenia, we found bipolar disorder with psychosis to 
have lower emotional expressivity compared to bipolar disorder without 
psychosis. 
• Findings also indicate that the SANS preserves its ability to measure 
negative symptoms in a mixed clinical sample. 
• Results must be considered in the context of their limitations. First, 
cause and effect cannot be inferred because no participants were 
randomly assigned.  
• Furthermore, hypotheses regarding long-term vs. short term usage of 
nicotine could not be examined because past usage was not recorded.
• Additionally, these results were obtained in a population of 
symptomatically stable out-patients, and therefore do not necessarily 
extend to individuals with more severe symptoms.
• Future studies should included questionnaire assessing pattern of 
smoking, such as the Fagerström Test for Nicotine Dependence, when 
evaluating nicotine usage and may attempt to examine any relationship 
between nicotine and antipsychotic medications and their interaction on 
the negative symptoms of schizophrenia and bipolar disorder. 
Table 1. Demographic Information by Group
Total Bipolar Disorder Schizophrenia F p
BDN BDP
Age 38.3(12.8) 38.0(13.3) 36.0(12.6) 40.8(12.8) 1.71 0.18
λ p
Gender (% male) 37.9 29.2 29.8 54.0 0.06 0.57
Ethnicity (%) 0.16 0.16
Caucasian 42.1 39.6 36.2 50.0
African American 11.0 4.20 2.10 26.0
Hispanic/Latino 5.52 2.10 8.0 16.0
Asian American 1.38 0.00 2.10 2.00
Biracial 4.14 8.33 4.00 8.00
Table 2. Differences Between Groups on SANS Factor Scores Using MANOVA
SZ BDN BDP F p
SANS Factors
1 0.27 (1.29) -0.23 (0.73) -0.06 (0.84) 3.33 0.04
2 0.10 (1.14) 0.03 (0.98) -0.04 (0.81) 0.59 0.56
3 0.31 (1.27) -0.27 (0.36) -0.08 (1.01) 4.13 0.02
4 0.17 (1.14) -0.21 (0.83) 0.02 (0.95) 1.77 0.18
5 0.16 (1.32) -0.15 (0.64) -0.02 (0.73) 1.14 0.32
6 0.51 (1.16) -0.27 (0.85) -0.03 (0.70) 11.1 0.00
Table 3. Differences Between Nicotine Usage on HDRS and SANS Factor Scores Using MANOVA
SZ BDN BDP F p
Smoker Non-smoker Smoker Non-smoker Smoker Non-smoker
HDRS 10.6 (5.57) 7.92 (5.43) 7.78 (3.90) 9.33 (6.90) 9.92 (5.42) 8.11 (8.05) 0.72 0.61
SANS Factors
1 0.13 (1.32) 0.41 (1.25) -0.18 (0.83) -0.28 (0.63) -0.12 (0.80) 0.01 (0.88) 1.57 0.17
2 0.26 (1.22) -0.07 (1.06) 0.17 (1.11) -0.12 (0.84) 0.23 (0.99) -0.30 (0.63) 0.96 0.45
3 0.29 (1.18) 0.33 (1.35) -0.25 (0.34) -0.28 (0.38) -0.01 (1.28) -0.14 (0.74) 1.74 0.13
4 0.38 (1.18) -0.05 (1.09) -0.31 (0.86) -0.11 (0.79) 0.14 (1.12) -0.10 (0.78) 1.41 0.22
5 0.32 (1.83) -0.01 (0.80) -0.22 (0.49) -0.08 (0.78) -0.00 (0.68) -0.04 (0.77) 0.77 0.57
6 0.36 (1.11) 0.65 (1.20) -0.35 (0.58) -0.18 (1.11) -0.26 (0.66) -0.29 (0.73) 4.70 0.00
Table 4. Correlation Between SANS Factor Scores and HDRS
SANS Factors 
1 2 3 4 5 6
HDRS
r-value -0.14 0.41** -0.03 0.30** 0.09 0.14
AT = Attention.
Notes: SZ= Schizophrenia; BDN = Bipolar Disorder without Psychosis; BDP = Bipolar Disorder with Psychosis; Factor 1 = 
Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5 = Affective 
Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention;
Method
Notes: SZ= Schizophrenia; BDN = Bipolar Disorder without Psychosis; BDP = Bipolar Disorder with Psychosis; Factor 1 = 
Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5 = Affective 
Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention; HDRS = Hamilton Depression Rating Scale
Notes: Factor 1 = Affective Flattening; Factor 2 = Anhedonia-Asociality; Factor 3 = Alogia; Factor 4 = Avolition-Apathy; Factor 5 
= Affective Flattening, Alogia, and Avolition-Apathy; Factor 6 = Attention; HDRS = Hamilton Depression Rating Scale; 
**Correlation is significant at the 0.01 level (2-tailed).
Measures and Procedures
• Structured Clinical Interview for DSM-IV (SCID) was used to confirm diagnoses. 
Participants were then asked if they currently used tobacco; those who endorsed tobacco 
use were categorize as the  nicotine group while those who do not smoke were put in the 
non-nicotine group. The current study examined current usage of nicotine. 
• Negative Symptoms were evaluated using the Scale for the Negative Symptoms 
(SANS), which can be divided into two subscales, including motivation/pleasure and 
emotional expressivity. 
• The Hamilton Depression Rating Scale (HDRS) was used to measure symptoms of 
depression; higher ratings indicate more severe or more frequent symptoms. 
Data Analysis:
• Principal Component Analysis (PCA) with varimax rotation was used to identify 
groupings of SANS subscales. 
• A  multivariate ANOVA  was used to evaluate differences between groups, smokers, and 
HDRS on SANS Factor Scores. Differences between smokers on HDRS was also 
measured.
• Correlation between SANS Factor Scores and HDRS were conducted for the total 
sample.  
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